Please provide your email address to receive an email when new articles are posted on . The goal of a new EULAR initiative linking trial centers across Europe is quicker, more efficient clinical ...

Please provide your email address to receive an email when new articles are posted on . A new trial center network and two major data collection projects are among recent EULAR initiatives for ...

Create a network of clinical trial centres, accessible to all investigators and sponsors from both public and private sectors. Build capacity and training in clinical trials and experimental medicine ...

RA is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems. Treating RA ...

-- Patients with moderate-to-severe systemic disease activity (ESSDAI score ≥5) treated with dazodalibep experienced improvement in their disease activity (6.3-point reduction) compared to those who ...

COPENHAGEN -- A randomized trial reported here appears to confirm that, contrary to guidance from major rheumatology societies, years-long use of corticosteroids in older rheumatoid arthritis (RA) ...

NEW YORK and MELBOURNE, Australia, June 22, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) announced that results from the randomized, placebo-controlled 48-patient Phase 2 trial ...

BARCELONA -- Aggressive treatment for patients who look like they may soon develop rheumatoid arthritis (RA) appears very effective for certain patients, according to long-term data presented here ...

3-month Phase 2 data continue to show SEL-212 (SVP-Rapamycin + pegsiticase) may present a superior product profile over current FDA-approved chronic severe gout therapy with serum uric acid (SUA) ...

EULAR - The European Alliance of Associations for Rheumatology - has developed a new disease activity score that quantifies the level of disease activity in people with antiphospholipid syndrome (APS) ...

-- Patients with moderate-to-severe systemic disease activity (ESSDAI score ≥5) treated with dazodalibep experienced improvement in their disease activity (6.3-point reduction) compared to those who ...